Maybe the answer's in there and I just didn't hear it, but the question was whether there were possibly products that have gotten through because there were inadequate clinical trials. Are there drugs out there that we're going to find out a couple of years from now are problematic, because the department wasn't doing the kind of clinical trials that it should have been doing? That's what I'm asking.
On February 12th, 2007. See this statement in context.